Jytaglen

Sitagliptin, the active ingredient in Jytaglen, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It is prescribed to improve blood glucose control in adults with type 2 diabetes mellitus, typically as part of a comprehensive management plan that includes diet and exercise.

GNH USA supplies Jytaglen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures product quality through rigorous quality‑assurance processes and provides reliable logistics for global distribution throughout.

Sitagliptin is used in the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by elevated blood glucose.

- Type 2 diabetes mellitus: improves glycemic control when combined with diet, exercise and other antidiabetic agents. - Adjunct therapy with metformin: provides additional reduction in HbA1c for patients inadequately controlled on metformin alone. - Combination with insulin: helps lower post‑prandial glucose excursions while reducing required insulin dose.

Sitagliptin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nasopharyngitis: inflammation of the nasal passages and throat. - Headache: mild to moderate head pain. - Upper respiratory tract infection: cough and congestion. - Nausea: feeling of stomach upset.

Serious or Rare Side Effects: - Pancreatitis: inflammation of the pancreas, potentially severe. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Joint pain: unexplained arthralgia that may be disabling. - Hepatic injury: rare liver enzyme elevations or hepatitis.

When prescribing sitagliptin, clinicians should consider several safety precautions to minimize risk.

- Renal function: assess and monitor because dose adjustment may be needed in impairment. - Pancreatitis history: evaluate for prior episodes and discontinue if symptoms develop. - Hypersensitivity: discontinue at first sign of rash, swelling or anaphylaxis. - Concomitant insulin or sulfonylureas: monitor for hypoglycemia and adjust doses. - Elderly patients: use with caution due to potential for renal decline. - Store at room temperature: keep in the original container, protect from moisture and heat.

Sitagliptin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of hypoglycemia. - Rifampin: strong enzyme inducer that markedly reduces sitagliptin exposure. - Strong diuretics (e.g., furosemide): may diminish glucose‑lowering effect.

Moderate Interactions (Monitor Closely): - ACE inhibitors: monitor potassium levels and renal function. - Warfarin: observe INR for possible changes. - Digoxin: check serum levels as sitagliptin may affect clearance.